Spyre Therapeutics, Inc. (SYRE) SEC Filings & Earnings Calls

Dilution from equity offering may pressure existing shareholders.

“Issuance of 4,117,648 shares (plus up to 617,647 option shares) increases share count.”

Early-stage data; Part B combination data not yet available; regulatory and commercial risks remain.

“Part B topline data expected in 2027; safety profile consistent with class.”

SPY072 did not meet internal bar for monotherapy development in RA, indicating potential setback for this indication.

“Magnitude of effect did not meet Company's target to prioritize monotherapy development of SPY072 in RA.”

Clinical hold on RGX-121 (separate company) but not directly relevant to Spyre.

“Not applicable.”

Clinical-stage company with no approved products; regulatory and trial risks.

“Clinical-stage biotechnology company; no revenue from product sales.”

High R&D spending and operating losses

“R&D expense increased to $65.5M in Q2 2026 from $40.1M in Q2 2025; net loss of $36.2M.”

CVR liability uncertainty

“CVR liability increased to $38.6M from $26.7M at Dec 2025, driven by milestone achievements.”

Dilution risk from ATM program

“New ATM program allows sale of up to $500M in common stock.”

Activist exit risk

“On June 23, 2026, Fund II sold in a block trade a total of 4,684,781 shares of Common Stock at a price of $85.31 per share.” · word for word

Activist exit risk

“On June 23, 2026, Fund II sold in a block trade a total of 4,684,781 shares of Common Stock at a price of $85.31 per share.” · word for word

Two SAEs reported but deemed not drug-related; safety profile consistent with TL1A class.

“SAEs: UC exacerbation and worsening heart failure, both not drug-related.”

Clinical-stage biotech with no approved products; reliance on pipeline success.

“Company is a clinical-stage biotechnology company with no approved products; all programs are in Phase 2 trials.”

Dilution risk from recent equity offering.

“Raised $463 million through an underwritten public offering of common stock, increasing share count.”

No revenue, history of losses

“The Company is a clinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products.” · word for word

CVR liability volatility

“The change in fair value between December 31, 2025 and March 31, 2026 was a $30.3 million increase, primarily driven by the achievement of certain milestones and changes in the likelihood of achievement of certain milestones.” · word for word

Dilution to existing shareholders from new share issuance.

“6.5M primary shares issued, plus 975k option shares.”

Clinical and regulatory risks remain; Phase 2 data may not predict Phase 3 success.

“Forward-looking statements highlight risks in drug development, regulatory approval, and competition.”

ATM program suspended, limiting near-term equity financing flexibility.

“Company suspended and terminated the ATM Prospectus.”

Material Weakness in Internal Controls

“a material weakness identified as of December 31, 2024 related to the Company not designing and maintaining effective controls to evaluate the treatment of the Company’s Series A non-voting convertible preferred stock ("Series A Preferred Stock") and Series B non-voting convertible preferred stock ("Series B Preferred Stock") for the purpose of calculating e” · word for word

Pre-revenue Clinical Stage Company

“Spyre is a recently public, pre-revenue clinical stage biotechnology company” · word for word

Related Party Concentration

“Fairmount beneficially owns more than 5% of a class of our voting securities, has two seats on our Board (held by Peter Harwin and Tomas Kiselak) and beneficially owns more than 5% of Paragon.” · word for word

Stock Price Volatility

“like other companies in the biotechnology industry, faces extreme stock price and volume fluctuations that are often unrelated or disproportionate to our operating performance.” · word for word

Clinical-stage company with no approved products or revenue; success depends on trial outcomes

“Company is a clinical-stage biotechnology company; no revenue or earnings metrics reported”

Pre-revenue biotechnology company with no approved products

“The Company is a clinical stage biotechnology company with a limited operating history, and due to its significant research and development expenditures, the Company has generated operating losses since its inception and has not generated any revenue from the commercial sale of any products.” · word for word

Need for additional financing

“The Company will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can be produced, marketed and sold.” · word for word

Clinical trial and regulatory uncertainty

“uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with our clinical trial design, interpretation of data and our ongoing or planned clinical trials for our product candidates” · word for word

Clinical-stage company with no approved products or revenue; dependent on trial success

“clinical-stage biotechnology company; no revenue mentioned”